{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:02:37Z","timestamp":1793037757024,"version":"4.5.0"},"reference-count":78,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment for breast cancer, including endocrine therapies, can contribute to bone loss and increase the risk of osteoporosis and fractures. Management of bone health in patients with cancer is often coordinated between oncologists, endocrinologists, and primary care physicians. In this article, we discuss the approach to screening for fracture risk among patients initiating treatments for breast cancer and recommendations for lifestyle modifications to optimize bone health. We will review 3 indications for pharmacologic bone-targeted therapies: prevention of cancer treatment-induced bone loss, adjuvant therapy to reduce recurrence, and management of bone metastases.<\/jats:p>","DOI":"10.1210\/clinem\/dgae404","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T12:29:47Z","timestamp":1718195387000},"page":"e1902-e1910","source":"Crossref","is-referenced-by-count":5,"title":["Approach to Bone Health in the Patient With Breast Cancer"],"prefix":"10.1210","volume":"109","author":[{"given":"Yasaman","family":"Motlaghzadeh","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Stanford University School of Medicine , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-4503","authenticated-orcid":false,"given":"Joy Y","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Stanford University School of Medicine , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"5","key":"2024091609270295400_dgae404-B1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors: results from the Women's health initiative observational study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"2024091609270295400_dgae404-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11914-015-0277-9","article-title":"Adjuvant endocrine therapy and bone health in breast cancer","volume":"13","author":"Clines","year":"2015","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"2024091609270295400_dgae404-B3","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9793","key":"2024091609270295400_dgae404-B4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"2024091609270295400_dgae404-B5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2012.11.011","article-title":"The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis","volume":"53","author":"Nelson","year":"2013","journal-title":"Bone"},{"issue":"10","key":"2024091609270295400_dgae404-B6","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgaa463","article-title":"Challenges in preventing bone loss induced by aromatase inhibitors","volume":"105","author":"Rachner","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2024091609270295400_dgae404-B7","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisd\u00f3ttir","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024091609270295400_dgae404-B8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024091609270295400_dgae404-B9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","article-title":"Bone health during endocrine therapy for cancer","volume":"6","author":"Rachner","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2024091609270295400_dgae404-B10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2024091609270295400_dgae404-B11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","article-title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","volume":"22","author":"Eastell","year":"2011","journal-title":"Ann Oncol"},{"key":"2024091609270295400_dgae404-B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/bonekey.2015.60","article-title":"Cancer treatment-induced bone loss in women with breast cancer","volume":"4","author":"Hadji","year":"2015","journal-title":"Bonekey Rep"},{"issue":"2","key":"2024091609270295400_dgae404-B13","doi-asserted-by":"crossref","first-page":"151280","DOI":"10.1016\/j.soncn.2022.151280","article-title":"Direct and indirect mechanisms of chemotherapy-induced bone loss in adjuvant breast cancer: an integrative review","volume":"38","author":"Rayner-Myers","year":"2022","journal-title":"Semin Oncol Nurs"},{"issue":"31","key":"2024091609270295400_dgae404-B14","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024091609270295400_dgae404-B15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American cancer society\/American society of clinical oncology breast cancer survivorship care guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024091609270295400_dgae404-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"issue":"12","key":"2024091609270295400_dgae404-B17","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"33","key":"2024091609270295400_dgae404-B18","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1200\/JCO.2008.17.7451","article-title":"Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis","volume":"26","author":"Camacho","year":"2008","journal-title":"J Clin Oncol"},{"issue":"22","key":"2024091609270295400_dgae404-B19","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2008.20.2549","article-title":"Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance","volume":"27","author":"Mann","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024091609270295400_dgae404-B20","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2024091609270295400_dgae404-B21","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","article-title":"Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer","volume":"28","author":"Waqas","year":"2021","journal-title":"J Bone Oncol"},{"issue":"9","key":"2024091609270295400_dgae404-B22","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00198-022-06458-z","article-title":"The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors","volume":"33","author":"Bailey","year":"2022","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024091609270295400_dgae404-B23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jbmr.4250","article-title":"Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer","volume":"36","author":"Lu","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024091609270295400_dgae404-B24","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/jbmr.3726","article-title":"Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study","volume":"34","author":"Leslie","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2024091609270295400_dgae404-B25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34 Suppl 1","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2024091609270295400_dgae404-B26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jbo.2013.08.001","article-title":"Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN trial","volume":"2","author":"Lomax","year":"2013","journal-title":"J Bone Oncol"},{"issue":"2","key":"2024091609270295400_dgae404-B27","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","article-title":"Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial","volume":"12","author":"Markopoulos","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"6","key":"2024091609270295400_dgae404-B28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024091609270295400_dgae404-B29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","article-title":"Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial","volume":"26","author":"Greenspan","year":"2015","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024091609270295400_dgae404-B30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jbo.2012.06.002","article-title":"Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial","volume":"1","author":"Lester","year":"2012","journal-title":"J Bone Oncol"},{"issue":"9","key":"2024091609270295400_dgae404-B31","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024091609270295400_dgae404-B32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024091609270295400_dgae404-B33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"3","key":"2024091609270295400_dgae404-B34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2024091609270295400_dgae404-B35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"2024091609270295400_dgae404-B36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"2024091609270295400_dgae404-B37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"issue":"30","key":"2024091609270295400_dgae404-B38","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9992","key":"2024091609270295400_dgae404-B39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2024091609270295400_dgae404-B40","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024091609270295400_dgae404-B41","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024091609270295400_dgae404-B42","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024091609270295400_dgae404-B43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024091609270295400_dgae404-B44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2024091609270295400_dgae404-B45","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/jbmr.2918","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024091609270295400_dgae404-B46","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"7","key":"2024091609270295400_dgae404-B47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (national surgical adjuvant breast and bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024091609270295400_dgae404-B48","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"2024091609270295400_dgae404-B49","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"2024091609270295400_dgae404-B50","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djz215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"2024091609270295400_dgae404-B51","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care Ontario and American society of clinical oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024091609270295400_dgae404-B52","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"2024091609270295400_dgae404-B53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024091609270295400_dgae404-B54","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.21.02647","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update","volume":"40","author":"Eisen","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024091609270295400_dgae404-B55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2022.12.003","article-title":"Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12","volume":"180","author":"Beltran-Bless","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"2024091609270295400_dgae404-B56","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","article-title":"Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial","volume":"7","author":"Friedl","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"2024091609270295400_dgae404-B57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-021-06100-2","article-title":"Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer","volume":"187","author":"Jallouk","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"2024091609270295400_dgae404-B58","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of male breast cancer: ASCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024091609270295400_dgae404-B59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2024091609270295400_dgae404-B60","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"15","key":"2024091609270295400_dgae404-B61","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"35","key":"2024091609270295400_dgae404-B62","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024091609270295400_dgae404-B63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"2024091609270295400_dgae404-B64","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"28","key":"2024091609270295400_dgae404-B65","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024091609270295400_dgae404-B66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"2024091609270295400_dgae404-B67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2013.05.001","article-title":"A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer","volume":"2","author":"Hutton","year":"2013","journal-title":"J Bone Oncol"},{"issue":"2","key":"2024091609270295400_dgae404-B68","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00520-020-05556-0","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer"},{"issue":"4","key":"2024091609270295400_dgae404-B69","doi-asserted-by":"crossref","first-page":"pky062","DOI":"10.1093\/jncics\/pky062","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"12","key":"2024091609270295400_dgae404-B70","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1245\/s10434-021-10227-3","article-title":"Survival outcomes among patients with metastatic breast cancer: review of 47,000 patients","volume":"28","author":"Taskindoust","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2024091609270295400_dgae404-B71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024091609270295400_dgae404-B72","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"2024091609270295400_dgae404-B73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"2024091609270295400_dgae404-B74","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"2024091609270295400_dgae404-B75","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1007\/s00520-021-06714-8","article-title":"Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers","volume":"30","author":"Alzahrani","year":"2022","journal-title":"Support Care Cancer"},{"issue":"35","key":"2024091609270295400_dgae404-B76","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American society of clinical oncology-cancer care Ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024091609270295400_dgae404-B77","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"25","key":"2024091609270295400_dgae404-B78","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-Related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae404\/58418694\/dgae404.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae404\/59135790\/dgae404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae404\/59135790\/dgae404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:30:07Z","timestamp":1726479007000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/10\/e1902\/7691691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":78,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae404","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,12]]}}}